Showing 131-140 of 3189 results for "".
- First Patient Dosed in Phase 1b/2 Trial of Dermaliq Therapeutics's DLQ02 for PsOhttps://practicaldermatology.com/news/first-patient-dosed-in-phase-1b2-trial-of-dermaliq-therapeuticss-dlq02-for-pso/2461310/The first patient has been dosed in a Phase 1b/2a trial with DLQ02, a topical calcineurin inhibitor, Dermaliq Therapeutics, Inc. reports. The trial is designed to evaluate the safety, systemic absorption, pharmacodynamics, and clinical efficacy of DLQ02 in patients with plaqu
- New Time-Limited Double Allē Points Promotion Launched for Juvederm Usershttps://practicaldermatology.com/news/new-double-alle-points-promotion-for-juvederm-users/2461307/Consumers can earn double points in Allē, Allergan Aesthetics' loyalty rewards program, when treated with two or three syringes from the JUVÉDERM Collection of Fillers during the same visit. Allē points can be redeemed for future Allē-eligible treatments or products.&nb
- Rodan + Fields Gives Back: Company Announces More Donations from Youth Empowerment Fundhttps://practicaldermatology.com/news/rodan-fields-gives-back-company-announces-more-donations-from-youth-empowerment-fund/2461300/Rodan + Fields has announced the second round of donations from the Youth Empowerment Fund through their support of the Prescription for Change project. Launched in August 2021, the Fund will invest a total of $5 Million over three years to empower young people to l
- Dial Joins Forces with DonorsChoose and TeacherLists to Support Teachershttps://practicaldermatology.com/news/dial-joins-forces-with-donorschoose-and-teacherlists-to-supoort-teachers/2461264/Dial is doubling down on efforts to support teachers with a back-to-school marketing campaign. For the second year in a row, Dial has partnered with
- Barbie Launches Ken Doll with Vitiligohttps://practicaldermatology.com/news/barbie-launches-ken-doll-with-vitiligo/2461197/Mattel, the parent company for Barbie, will include a Ken doll with vitiligo as part of their 2022 Fashionistas line. The Barbie Fashionistas line includes Barbie dolls with more variety of skin tones, eye colors, hair colors and textures, body types, disabilities, and fashions.
- Dove, Crown Coalition Applaud U.S. House of Representatives for Passing Crown Acthttps://practicaldermatology.com/news/dove-crown-coalition-applaud-us-house-of-representatives-for-passing-crown-act/2461116/The CROWN Coalition, a national alliance founded by Dove, National Urban League, Western Center on Law & Poverty and Color of Change, along with more than 90 members of the CROWN Coalition praise the U.S. House of Representatives for passing the CROWN A
- Case Study Highlights Possible Role for Minimal Dose Radiotherapy in Severe Acne Keloidalis Nuchaehttps://practicaldermatology.com/news/case-study-highlights-possible-role-for-minimal-dose-radiotherapy-in-severe-acne-keloidalis-nuchae/2461021/Minimal dose radiotherapy may offer new hope for severe acne keloidalis nuchae (AKN), according to research in the Journal of the American Academy of Dermatology Case Reports. The study found t
- Dermavant: First Patient Dosed in Phase 3 Study of Tapinarof in ADhttps://practicaldermatology.com/news/dermavant-first-patient-dosed-in-phase-3-study-of-tapinarof-in-ad/2460925/The first patient has been dosed in the Phase 3, double-blind, vehicle-controlled pivotal study of tapinarof for the treatment of atopic dermatitis (AD). Tapinarof is an investigational, novel, therapeutic aryl hydrocarbon receptor modulating agent, in development by
- Sasakawa Leprosy (Hansen's Disease) Launches New "Don't Forget Leprosy" Initiativehttps://practicaldermatology.com/news/sasakawa-leprosy-hansens-disease-new-initiative-dont-forget-leprosy/2460872/Sasakawa Leprosy (Hansen's Disease) Initiative is launching a campaign called "Don't Forget Leprosy" urging that activities against the disease are not sidelined amid the ongoing coronavirus pandemic. Beginning with a webinar on Aug. 4, 2021, the approximately 10-
- Sirnaomics Doses First Patient in Phase 2b Study of STP705 for Treatment of Squamous Cell Skin Cancerhttps://practicaldermatology.com/news/sirnaomics-doses-first-patient-in-phase-2b-study-of-stp705-for-treatment-of-squamous-cell-skin-cancer/2460857/Sirnaomics, Inc. dosed the first patient in a Phase 2b study of the company's drug candidate, STP705, for the trea